How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liraglutide-and-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Liraglutide and metformin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liraglutide and metformin (Liraglutide and metformin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist + biguanide combination. Area: Endocrinology / Diabetes.

marketed GLP-1 receptor agonist + biguanide combination GLP-1 receptor; metformin complex I inhibitor Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Liraglutide and metformin (Liraglutide and metformin) — Peking University Third Hospital. Liraglutide stimulates insulin secretion via GLP-1 receptor activation while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liraglutide and metformin TARGET	Liraglutide and metformin	Peking University Third Hospital	marketed	GLP-1 receptor agonist + biguanide combination	GLP-1 receptor; metformin complex I inhibitor
Liraglutide + metformin	Liraglutide + metformin	University Medical Centre Ljubljana	marketed	GLP-1 receptor agonist + biguanide combination	GLP-1 receptor; metformin targets mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist + biguanide combination class)

Peking University Third Hospital · 1 drug in this class
University Medical Centre Ljubljana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liraglutide and metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/liraglutide-and-metformin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab